CDT-raloxifene - SCOLR Pharma

Drug Profile

CDT-raloxifene - SCOLR Pharma

Alternative Names: CDT®-raloxifene; Controlled Delivery Technology®-raloxifene

Latest Information Update: 07 Aug 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SCOLR Pharma
  • Class Antineoplastics; Calcium regulators; Osteoporosis therapies; Small molecules; Stilbenes
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Jun 2013 SCOLR Pharma ceases its business operations
  • 30 Jun 2013 Discontinued - Phase-I for Osteoporosis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top